Expectorant Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032
상품코드:1637054
리서치사:Fairfield Market Research
발행일:2025년 01월
페이지 정보:영문 178 Pages
라이선스 & 가격 (부가세 별도)
한글목차
세계 거담제 시장은 호흡기질환의 유병률 증가와 효과적인 증상 관리에 대한 인식이 높아짐에 따라 CAGR 4.20%(연평균 4.00%)로 성장하여 2025년에는 182억 4,000만 달러, 2032년에는 243억 2,000만 달러에 달할 것으로 예상됩니다. 000만 달러에 달할 것으로 예상됩니다. 거담제는 만성폐쇄성폐질환(COPD), 천식, 기관지염 등의 증상을 앓고 있는 환자의 점액 배출을 촉진하고 호흡의 편안함을 향상시키는 등 호흡기 건강관리에서 매우 중요한 역할을 합니다.
거담제는 기도에서 점액 배출을 촉진하여 호흡기질환 관리에 필수적인 역할을 합니다. 기침과 코막힘을 완화하는 효과가 있어 만성 및 급성 호흡기 치료에 필수적입니다. 이 시장의 성장 궤적은 약물 제형의 지속적인 혁신과 첨단 약물전달 메커니즘의 통합에 의해 뒷받침되고 있습니다.
COPD, 천식 등 만성질환이 점점 더 흔해지면서 거담제 수요를 견인하고 있습니다. 호흡기 건강이 전 세계적으로 우선순위로 떠오르면서 이러한 약물은 증상 관리의 중요한 부분으로 자리 잡고 있습니다. 조기 및 효과적인 증상 관리의 이점에 대한 인식이 높아짐에 따라 시장 성장을 촉진하고 있습니다. 예방 의료 관행은 합병증을 피하기 위해 적시에 거담제를 사용하는 것을 강조하고 있습니다. 제약회사들은 혁신적인 거담제 개발에 많은 투자를 하고 있으며, 이는 시장의 잠재력을 더욱 높이고 있습니다.
세계의 거담제 시장에 대해 조사했으며, 시장 개요와 함께 약제 종류별, 제형별, 제품 종류별, 유통 채널별, 지역별 동향, 시장 진입 기업의 경쟁 동향 등의 정보를 전해드립니다.
목차
제1장 주요 요약
제2장 시장 개요
시장 정의와 세분화
시장 역학
밸류체인 분석
Porter's Five Forces 분석
COVID-19의 영향 분석
PESTLE 분석
제3장 2025년 가격 분석
제4장 세계의 거담제 시장 전망, 2019-2032년
세계의 거담제 시장 전망, 약물 유형별, 금액(10억 달러), 수량(100만 개), 2019-2032년
세계의 거담제 시장 전망, 제형별, 금액(10억 달러), 수량(100만 개), 2019-2032년
세계의 거담제 시장 전망, 제품 유형별, 금액(10억 달러), 수량(100만 개), 2019-2032년
세계의 거담제 시장 전망, 유통 채널별, 금액(10억 달러), 수량(100만 개), 2019-2032년
세계의 거담제 시장 전망, 지역별, 금액(10억 달러), 수량(100만 개), 2019-2032년
제5장 북미의 거담제 시장 전망, 2019-2032년
제6장 유럽의 거담제 시장 전망, 2019-2032년
제7장 아시아태평양의 거담제 시장 전망, 2019-2032년
제8장 라틴아메리카의 거담제 시장 전망, 2019-2032년
제9장 중동 및 아프리카의 거담제 시장 전망, 2019-2032년
제10장 경쟁 구도
기업 시장 점유율 분석, 2025년
경쟁 대시보드
기업 개요
Abbott Laboratories
Acella Pharmaceuticals LLC
Astrazeneca Plc.
Cipla Limited
Dabur India Ltd
Glenmark Pharmaceuticals Limited
Johnson and Johnson
Merck KGaA
Novartis International AG
기타
제11장 부록
KSM
영문 목차
영문목차
The global expectorant drugs market is set to experience significant growth, driven by the increasing prevalence of respiratory disorders and heightened awareness regarding effective symptom management. With an anticipated expansion at a CAGR of 4.20%, the market is projected to reach USD 18.24 billion in 2025 and USD 24.32 billion by 2032. Expectorant drugs play a pivotal role in respiratory healthcare, facilitating mucus clearance and enhancing breathing comfort for patients dealing with conditions like chronic obstructive pulmonary disease (COPD), asthma, and bronchitis.
Market Insights Expectorant drugs are essential in managing respiratory ailments by promoting the expulsion of mucus from the respiratory tract. Their efficacy in alleviating coughs and congestion makes them indispensable in both chronic and acute respiratory care. The market's growth trajectory is bolstered by continuous innovation in drug formulations and the integration of advanced drug delivery mechanisms.
Key Market Drivers
1. Rising Prevalence of Respiratory Disorders: Chronic conditions like COPD and asthma are increasingly common, driving demand for expectorant drugs. With respiratory health gaining priority globally, these medications are becoming a critical part of symptom management.
2. Awareness of Early Intervention: Growing recognition of the benefits of early and effective symptom management is propelling market growth. Preventive healthcare practices emphasize the timely use of expectorant drugs to avoid complications.
3. Research and Development Advancements: Pharmaceutical companies are investing heavily in the development of innovative expectorant formulations, further enhancing the market's potential.
Business Opportunities
1. Innovative Formulations and Combination Therapies: The development of advanced drug delivery systems, such as extended-release formulations, offers promising revenue opportunities. Combination therapies incorporating expectorants with bronchodilators or anti-inflammatory agents can address multiple aspects of respiratory conditions.
2. Targeted Products for Diverse Demographics: Companies can expand their product portfolios by developing specialized expectorant drugs tailored for pediatric, geriatric, and condition-specific needs. This diversification addresses a broader range of patient requirements and fosters market penetration.
3. Expansion into Emerging Markets: Rapid urbanization and increasing healthcare awareness in regions like South Asia and the Pacific present lucrative opportunities for market growth.
Regional Analysis
1. Europe: Europe holds a dominant position in the expectorant drugs market due to its robust healthcare infrastructure and high prevalence of respiratory disorders. Advanced medical facilities and proactive respiratory health management contribute to the region's strong foothold.
2. South Asia and the Pacific: This region is anticipated to witness the fastest growth, driven by urbanization, environmental challenges, and an increasing burden of respiratory ailments. Enhanced healthcare access and rising awareness further support market expansion.
3. North America and East Asia: These regions also show significant market potential, attributed to established pharmaceutical industries and growing healthcare expenditure.
Key Players The expectorant drugs market is characterized by intense competition among leading pharmaceutical companies. Notable players include:
Abbott Laboratories
Acella Pharmaceuticals LLC
AstraZeneca Plc.
Cipla Limited
Dabur India Ltd
Glenmark Pharmaceuticals Limited
Johnson & Johnson
Merck KGaA
Novartis International AG
Pfizer Inc.
Procter & Gamble Co.
These companies focus on strategic partnerships, innovative product launches, and geographical expansion to strengthen their market position.
Recent Developments
1. Product Launches:
In October 2023, Efficient Laboratories introduced "ROMPR PECHITO," an OTC medicine designed for pediatric cold relief.
In September 2023, Genexa launched new clean OTC kids' medicines, emphasizing safety and effectiveness, which resonated well with health-conscious consumers.
Market SegmentationThe expectorant drugs market can be categorized as follows:
1. By Drug Type:
Secretion Enhancers: Includes potassium citrate, guaiphenesin, and ammonium chloride.
Mucolytics: Comprising bromhexine, ambroxol, and acetyl cysteine.
2. By Dosage Form:
Oral Solid: Tablets and capsules dominate due to patient convenience and precise dosing.
Oral Liquid: Fast-acting formulations gaining popularity for rapid symptom relief.
Inhalants: Preferred for targeted respiratory treatment.
3. By Product Type:
Over-The-Counter (OTC): Leading segment due to accessibility and ease of use.
Prescription Drugs: Essential for managing complex respiratory conditions.
4. By Distribution Channel:
Hospital Pharmacies: Highest sales due to direct integration with healthcare facilities.
Online Pharmacies: Fastest-growing segment, driven by digital convenience and accessibility.
Retail Stores and Drug Stores: Continues to be a critical distribution channel.
5. By Region:
North America
Europe
East Asia
South Asia & Oceania
Latin America
Middle East & Africa
Table of Contents
1. Executive Summary
1.1. Global Expectorant Drugs Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value and Volume, 2025
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter's Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. PESTLE Analysis
3. Price Analysis, 2025
3.1. Global Average Price Analysis, by Drug Type/ Material, US$ Per Unit, 2025
